Pharmaceutical Industry Faces Setback as D.C. Circuit Upholds Medicare Price Negotiation Authority
The D.C. Circuit’s recent decision represents another chapter in the ongoing legal tussle between the pharmaceutical industry and the federal government over Medicare’s newly minted pricing negotiation capabilities. While the pharmaceutical sector faces a setback, the ruling provides nuanced insights that may inform future litigation strategies. The court’s affirmation aligns with the judgments of other…